Clinical Trials · NCT00500110
Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- M.D. Anderson Cancer Center
- Enrollment
- 39
- Start date
- Jun 2003
- Locations
- 1 site, United States
- Primary endpoint
- Number of Participants Achieving Pathological Complete Response